Pfizer's Future in 5 Years: Top-Selling Drugs, Oncology Focus, and Efficiency Gains

Pfizer is expected to have a different lineup of top-selling drugs in 2030, with a heavier focus on oncology. The company will likely be more efficient and growing modestly. Pfizer will still be paying a great dividend five years from now. Pfizer's top-selling drugs today include Eliquis, Prevnar vaccines, Vyndaqel/Vyndamax franchise, and Ibrance. The list will likely change in 2030 due to patent expirations and new drugs being developed.

Pfizer (PFE) is expected to undergo significant changes in its top-selling drug lineup by 2030, with a heavier focus on oncology. The company is also anticipated to become more efficient and continue to grow modestly, while maintaining a robust dividend program.

Top-Selling Drugs in 2030

Pfizer's current top-selling drugs include Eliquis, Prevnar vaccines, Vyndaqel/Vyndamax franchise, and Ibrance. However, by 2030, this lineup is expected to change due to patent expirations and the introduction of new drugs. Eliquis and Prevnar 13 are set to lose their U.S. patent protection in 2023, while Ibrance's patent expires in 2027. Pfizer is hoping to extend the patent for Vyndaqel/Vyndamax until 2028, pending a patent term extension [1].

To fill the gap left by these patent expirations, Pfizer has already introduced a successor to Prevnar 13, known as Prevnar 20, and has added several promising drugs to its portfolio through acquisitions and internal R&D. The company's pipeline includes several late-stage programs targeting cancer indications, which are expected to contribute significantly to its future drug sales [2].

Oncology Focus

One of the most notable changes in Pfizer's drug lineup by 2030 is the increased focus on oncology. Sales for drugs like Padcev (bladder cancer), Lorbrena (lung cancer), Elrexfio (multiple myeloma), and Talzenna (breast cancer) are already growing rapidly. Of the 30 late-stage programs in Pfizer's pipeline, 20 target cancer indications, including new target indications for existing drugs and promising new candidates like atirmociclib [1].

Efficiency and Growth

Pfizer is also expected to become more efficient by 2030. The company is focusing on optimizing its operations and expects to achieve savings of around $1.5 billion from its first phase of operational efficiency efforts, which are set to conclude by the end of 2027. Pfizer's overall goal was to achieve cost savings of $4.5 billion, but the company now expects the number to be $1.2 billion higher, thanks to leveraging automation and artificial intelligence [1].

These operational efficiencies are also expected to extend to Pfizer's R&D efforts. The company's CEO, Albert Bourla, has stated that Pfizer will intensify its commercial assessment and portfolio prioritization from early clinical development, focusing its investment and attention on potential blockbuster or mega-blockbuster therapies [1].

Modest Growth and Dividends

Overall, Pfizer is expected to be a bigger company in 2030, growing modestly beyond that point. The company's market cap could realistically approach $200 billion by 2030, up from around $137 billion today, despite the current negativity about its prospects baked into its share price [1].

Pfizer's management remains firmly committed to its dividend program, and it is expected to continue paying a great dividend in 2030. The company's CFO, Dave Denton, has stated that the dividend remains a critical component and a key component of its capital allocation strategy [1].

References

[1] https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/33770984/where-will-pfizer-pfe-be-in-5-years/
[2] https://www.fool.com/investing/2025/07/31/where-will-pfizer-pfe-be-in-5-years/